This page is part of the FHIR Specification (v3.3.0: R4 Ballot 2). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3 R2
Vocabulary Work Group | Maturity Level: N/A | Ballot Status: Informative |
Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.
<ValueSet xmlns="http://hl7.org/fhir"> <id value="v3-substanceAdminSubstitution"/> <meta> <lastUpdated value="2018-04-01T00:00:00.000+11:00"/> <profile value="http://hl7.org/fhir/StructureDefinition/shareablevalueset"/> </meta> <text> <status value="generated"/> <div xmlns="http://www.w3.org/1999/xhtml"> <p> Release Date: 2018-04-01</p> <table class="grid"> <tr> <td> <b> Level</b> </td> <td> <b> Code</b> </td> <td> <b> Display</b> </td> <td> <b> Definition</b> </td> </tr> <tr> <td> 1</td> <td> <span style="color: grey"> <i> (_ActSubstanceAdminSubstitutionCode)</i> </span> <b> <i> Abstract</i> </b> </td> <td> <a name="v3-substanceAdminSubstitution-_ActSubstanceAdminSubstitutionCode"> </a> </td> <td> Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. <br/> </td> </tr> <tr> <td> 2</td> <td> E <a name="v3-substanceAdminSubstitution-E"> </a> </td> <td> equivalent</td> <td> Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. <br/> </td> </tr> <tr> <td> 3</td> <td> EC <a name="v3-substanceAdminSubstitution-EC"> </a> </td> <td> equivalent composition</td> <td> Description: <br/> Substitution occurred or is permitted with another product that is a: <br/> pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: <br/> Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril </td> </tr> <tr> <td> 4</td> <td> BC <a name="v3-substanceAdminSubstitution-BC"> </a> </td> <td> brand composition</td> <td> Description: <br/> Substitution occurred or is permitted between equivalent Brands but not Generics <br/> Examples: <br/> Zestril for Prinivil Coumadin for Jantoven </td> </tr> <tr> <td> 4</td> <td> G <a name="v3-substanceAdminSubstitution-G"> </a> </td> <td> generic composition</td> <td> Description: Substitution occurred or is permitted between equivalent Generics but not Brands <br/> Examples: <br/> Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) </td> </tr> <tr> <td> 3</td> <td> TE <a name="v3-substanceAdminSubstitution-TE"> </a> </td> <td> therapeutic alternative</td> <td> Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. <br/> Examples: <br/> ranitidine for Tagamet </td> </tr> <tr> <td> 4</td> <td> TB <a name="v3-substanceAdminSubstitution-TB"> </a> </td> <td> therapeutic brand</td> <td> Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics <br/> > Examples: <br/> Zantac for Tagamet </td> </tr> <tr> <td> 4</td> <td> TG <a name="v3-substanceAdminSubstitution-TG"> </a> </td> <td> therapeutic generic</td> <td> Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands <br/> > Examples: <br/> Ranitidine for cimetidine </td> </tr> <tr> <td> 2</td> <td> F <a name="v3-substanceAdminSubstitution-F"> </a> </td> <td> formulary</td> <td> Description: This substitution was performed or is permitted based on formulary guidelines. <br/> </td> </tr> <tr> <td> 2</td> <td> N <a name="v3-substanceAdminSubstitution-N"> </a> </td> <td> none</td> <td> No substitution occurred or is permitted. <br/> </td> </tr> </table> </div> </text> <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-ballot-status"> <valueString value="External"/> </extension> <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm"> <valueInteger value="0"/> </extension> <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg"> <valueString value="vocab"/> </extension> <url value="http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution"/> <version value="2018-04-01"/> <name value="v3 Code System substanceAdminSubstitution"/> <status value="active"/> <experimental value="false"/> <date value="2018-04-01"/> <publisher value="HL7, Inc"/> <contact> <telecom> <system value="url"/> <value value="http://hl7.org"/> </telecom> </contact> <description value=" Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided."/> <immutable value="true"/> <compose> <include> <system value="http://hl7.org/fhir/v3/substanceAdminSubstitution"/> </include> </compose> </ValueSet>
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.